Layoffs Coming No Doubt

Quote
anonymous said:
Not doom and gloom, but no denying the inevitable. I’ve started my own side business so I’m working on my Plan B. But it helps to know timelines and what to expect.
Click to expand...

There are two kinds of people in pharma sales. First of all we all know this model is broken and layoffs industry wide will happen. That's a given. I find it amazing how those laid off look for another pharma job! Some people I know are on their 5th pharma job in less than ten years! When will they get it? Yeah I know the job pays well and has many perks. Who can stand the micromanaging environment and the threat of losing your job yearly? The other type of person is the one preparing for the layoff. Yeah they like it here. Maybe they are working on a side business. Maybe updating their resume. Maybe doing research into other sales fields. Maybe continuing their education. I've been preparing for this for many years and have a great side business. Most of it is managed on AZ's time. I'm coming to the end of my career here. I can't leave I'm hoping to max my retirement coin. Those of you in your 20's 30's and even 40's better plan an exit strategy or you will be fu*cked.
 




The highly anticipated EMPEROR-Preserved readout for Lilly/BI’s Jardiance (empagliflozin) was this morning, accompanied by a publication in NEJM and a Lilly press release - here again, it's the key question, is there an editorial? Yes: "SGLT-2 Inhibition in HF with a Preserved Ejection Fraction - A Win against a Formidable Foe." In patients with heart failure with preserved ejection fractions, Jardiance demonstrated a 21% relative risk reduction in the primary composite outcome of cardiovascular death or hospitalization for heart failure (HR = 0.79; 95% CI: 0.69-0.90; p<0.001) with consistent effects in patients with or without diabetes. This is the first study to meet a primary endpoint in heart failure with preserved ejection fraction. Additionally, we listened live to the EMPEROR-Pooled read out, along with a publication in NEJM, which found that Jardiance’s reduction of heart failure outcomes in EMPEROR-Preserved and EMPEROR-Reduced were highly concordant. However, empagliflozin only decreased the risk of major renal outcomes in EMPEROR-Reduced, not in EMPEROR-Preserved.
 




anonymous said:
The highly anticipated EMPEROR-Preserved readout for Lilly/BI’s Jardiance (empagliflozin) was this morning, accompanied by a publication in NEJM and a Lilly press release - here again, it's the key question, is there an editorial? Yes: "SGLT-2 Inhibition in HF with a Preserved Ejection Fraction - A Win against a Formidable Foe." In patients with heart failure with preserved ejection fractions, Jardiance demonstrated a 21% relative risk reduction in the primary composite outcome of cardiovascular death or hospitalization for heart failure (HR = 0.79; 95% CI: 0.69-0.90; p<0.001) with consistent effects in patients with or without diabetes. This is the first study to meet a primary endpoint in heart failure with preserved ejection fraction. Additionally, we listened live to the EMPEROR-Pooled read out, along with a publication in NEJM, which found that Jardiance’s reduction of heart failure outcomes in EMPEROR-Preserved and EMPEROR-Reduced were highly concordant. However, empagliflozin only decreased the risk of major renal outcomes in EMPEROR-Reduced, not in EMPEROR-Preserved.
Click to expand...
The SGLT2 class is all the same. Ask DeFranzo… he’s a Harvard dork, and he “discovered” them. Jardiance has better coverage, and our sales leadership sucks, so get ready to keep losing.
 




anonymous said:
The SGLT2 class is all the same. Ask DeFranzo… he’s a Harvard dork, and he “discovered” them. Jardiance has better coverage, and our sales leadership sucks, so get ready to keep losing.
Click to expand...
Don’t let Back Door Bob Gilot hear you say that. He will come after you, and he will make sure to use the HR wenches as his personal feminazi gestapo squad. Don’t cross him or else!
 








IMO it is more likely to be a "Back Door" layoff that is based on territory performance as happened widespread in November 2018. Several hundred nationwide lost their jobs then but, since it was "performance" based and not a structural reorganization, they received no WARN notice and only half the regular severance.......they still got the 6 months medical paid for as I recall. Unfortunate but that's the world we live in and the company we work for.
 
















anonymous said:
The SGLT2 class is all the same. Ask DeFranzo… he’s a Harvard dork, and he “discovered” them. Jardiance has better coverage, and our sales leadership sucks, so get ready to keep losing.
Click to expand...

You’re a moron. If Jardiance had the goods on us, this would have been much more than just an editorial. No eGFR slope means no class effect. Do your reading tootsie
 




anonymous said:
Well heck yes. Last year's layoff was in December. The like making our Christmas merry.
Click to expand...

If layoffs do happen then it’s long overdue. Pharma sales reps are useless overhead and, believe me, with the advances in AI and Geotargeting, they won’t be around much longer. Software doesn’t forge calls, or bribe doctors, or spend half the day at the gym and Starbucks, or threaten to sue the company at the first sign of trouble. It just works. 24-7. It doesn’t need a company car or health benefits. And it’s completely okay with being tracked around the clock.
 




anonymous said:
If layoffs do happen then it’s long overdue. Pharma sales reps are useless overhead and, believe me, with the advances in AI and Geotargeting, they won’t be around much longer. Software doesn’t forge calls, or bribe doctors, or spend half the day at the gym and Starbucks, or threaten to sue the company at the first sign of trouble. It just works. 24-7. It doesn’t need a company car or health benefits. And it’s completely okay with being tracked around the clock.
Click to expand...
LOL, dude what are you smoking???? I want some!!!
 




















RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 9, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Jardiance® (empagliflozin) as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.

The decision is based on results from the landmark EMPEROR-Preserved phase III trial, in which Jardiance demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction compared with placebo. The benefit was independent of ejection fraction or diabetes status. Results from EMPEROR-Preserved were presented at the European Society of Cardiology Congress 2021 on August 27 and published in The New England Journal of Medicine.

HFpEF accounts for approximately half of the more than 6 million heart failure cases in the U.S. No currently approved treatments have been clinically proven to significantly improve outcomes specifically for people with HFpEF.

"This Breakthrough Therapy designation underscores the potential of Jardiance to help fill a critical need for a clinically proven treatment for people with this highly prevalent, difficult-to-treat condition," said Mohamed Eid, M.D., M.P.H., M.H.A., vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. "Following the recent FDA approval of Jardiance for heart failure with reduced ejection fraction, this is another important milestone supporting the potential of Jardiance as the first therapy clinically proven to improve outcomes across the full heart failure spectrum."

According to the FDA, Breakthrough Therapy designation is designed to expedite the development and review of therapies that are intended to treat a serious condition where preliminary clinical evidence indicates potentially substantial improvement over available therapies on a clinically significant endpoint.

"Given the scarcity of treatment options for this debilitating condition, the benefits demonstrated in the EMPEROR-Preserved trial constituted a major clinical breakthrough," said Jeff Emmick, M.D., Ph.D., vice president, Product Development, Lilly. "Together with our Boehringer Ingelheim partners, we look forward to working closely with the FDA through this accelerated process to potentially bring Jardiance to adults with heart failure with preserved ejection fraction as soon as possible."

The FDA previously granted Fast Track designation for the development of Jardiance to reduce the risk of cardiovascular death and hospitalization for heart failure. This designation is for the EMPEROR program, which consists of the EMPEROR-Reduced and EMPEROR-Preserved trials. The EMPEROR-Reduced results formed the basis of the recent FDA approval for heart failure with reduced ejection fraction. Jardiance is not indicated for the treatment of HFpEF.

About EMPEROR-Preserved
EMPEROR-Preserved (NCT03057951) was a phase III international, randomized, double–blind trial that enrolled 5,988 adults with and without type 2 diabetes. All participants had heart failure (New York Heart Association [NYHA] functional class II, III or IV) and preserved ejection fraction (left ventricular ejection fraction > 40%).

Participants were randomized to once-daily Jardiance 10 mg (n=2997) or placebo (n=2991), on top of treatment with guideline-directed heart failure therapy. Median follow-up time was 26.2 months. The composite primary endpoint was defined as time to first event of cardiovascular death or hospitalization for heart failure.

Prioritizing Cardio-Renal-Metabolic Care
Through research and educational initiatives, Boehringer Ingelheim and Lilly are driven to redefine care for people with cardio-renal-metabolic conditions, a group of interconnected disorders that affect more than one billion people worldwide and are a leading cause of death.

The cardiovascular, renal (kidney) and metabolic systems are closely intertwined and share many of the same disease-related pathways. Dysfunction in one system may accelerate the onset of dysfunction in others, resulting in the progression of comorbid diseases such as type 2 diabetes, heart failure and chronic kidney disease. Conversely, improving the health of one system can lead to positive effects across the others and can help reduce the risk for further complications.

Understanding their interconnected nature, we are working to advance treatments for people with cardio-renal-metabolic conditions. It is only through a holistic approach to care that we can truly transform outcomes and restore the harmony among these critical systems.
 
















Top Bottom
Back
Quote